Ocular Therapeut (OCUL)

$11.01 +0.36 (3.38%)
Market Cap 2.34B
Revenue (ttm) 51.95M
Net Income (ttm) -265.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -511.92%
Debt to Equity Ratio 0.14
Volume 4,582,500
Avg Vol 2,788,456
Day's Range N/A - N/A
Shares Out 219.62M
Stochastic %K 93%
Beta 0.93
Analysts Strong Sell
Price Target $26.73

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Address:
14 Crosby Drive, 3rd Floor, Bedford, United States
SmokenTuna
SmokenTuna Aug. 19 at 12:52 PM
$OCUL going to blow!
0 · Reply
StarLord13
StarLord13 Aug. 19 at 12:49 PM
$OCUL
0 · Reply
Kashking03
Kashking03 Aug. 19 at 12:35 PM
$OCUL @ShortSuckieTuckie ..xbi is almost 3% up in PM..so di we see this run to 12$+
0 · Reply
nicky7
nicky7 Aug. 19 at 12:19 PM
$OCUL give me 25 eoy
0 · Reply
Aaronpell
Aaronpell Aug. 19 at 12:06 PM
$OCUL
0 · Reply
acdurham
acdurham Aug. 19 at 12:04 PM
$OCUL
0 · Reply
Jjarnold44
Jjarnold44 Aug. 19 at 12:03 PM
$OCUL.
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Aug. 19 at 11:37 AM
$OCUL
0 · Reply
lilcapman
lilcapman Aug. 18 at 10:00 PM
$OCUL https://x.com/semodough/status/2089822699052826728
0 · Reply
ES808
ES808 Aug. 18 at 7:46 PM
$OCUL 34 and +.
1 · Reply
Latest News on OCUL
Clear Street sees less competition for Ocular after EyePoint miss

2026-08-17T20:25:34.000Z - 1 day ago

Clear Street sees less competition for Ocular after EyePoint miss

EYPT

Ocular Therapeutix rises 10.4%

2026-08-17T14:05:49.000Z - 1 day ago

Ocular Therapeutix rises 10.4%

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2026, 4:05 PM EDT - 5 days ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)

2026-08-03T11:30:55.000Z - 16 days ago

Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Aug 3, 2026, 7:00 AM EDT - 16 days ago

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix Earnings release: Q2 2026

Aug 3, 2026, 7:00 AM EDT - 16 days ago

Ocular Therapeutix Earnings release: Q2 2026

Ocular Therapeutix Quarterly report: Q2 2026

Aug 3, 2026, 7:00 AM EDT - 16 days ago

Ocular Therapeutix Quarterly report: Q2 2026

Ocular Therapeutix Slides: Study Result presentation

Aug 2, 2026, 7:00 AM EDT - 17 days ago

Ocular Therapeutix Slides: Study Result presentation

Ocular Therapeutix Transcript: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Jul 22, 2026, 4:30 PM EDT - 27 days ago

Ocular Therapeutix Transcript: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Ocular Therapeutix Slides: American Society of Retina Specialists presentation

Jul 16, 2026, 7:00 AM EDT - 4 weeks ago

Ocular Therapeutix Slides: American Society of Retina Specialists presentation

Ocular Therapeutix Slides: Study result presentation

Jul 16, 2026, 7:00 AM EDT - 4 weeks ago

Ocular Therapeutix Slides: Study result presentation

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Jul 1, 2026, 7:00 AM EDT - 7 weeks ago

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright

2026-06-18T15:20:29.000Z - 2 months ago

Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright

Ocular Therapeutix price target raised to $30 from $24 at Baird

2026-06-18T10:31:11.000Z - 2 months ago

Ocular Therapeutix price target raised to $30 from $24 at Baird

Ocular Therapeutix Transcript: Investor Day 2026

Jun 17, 2026, 2:00 PM EDT - 2 months ago

Ocular Therapeutix Transcript: Investor Day 2026

Ocular Therapeutix Press release: FY 2026

Jun 17, 2026, 2:00 PM EDT - 2 months ago

Ocular Therapeutix Press release: FY 2026

Ocular Therapeutix Slides: FY 2026

Jun 17, 2026, 2:00 PM EDT - 2 months ago

Ocular Therapeutix Slides: FY 2026

Ocular Therapeutix trading resumes

2026-06-17T13:15:09.000Z - 2 months ago

Ocular Therapeutix trading resumes

Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA

2026-06-17T12:56:42.000Z - 2 months ago

Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA

Ocular Therapeutix to resume trading at 9:15 am ET

2026-06-17T12:56:01.000Z - 2 months ago

Ocular Therapeutix to resume trading at 9:15 am ET

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Jun 17, 2026, 8:45 AM EDT - 2 months ago

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Ocular Therapeutix trading halted, news pending

2026-06-17T12:40:11.000Z - 2 months ago

Ocular Therapeutix trading halted, news pending

Ocular Therapeutix Transcript: AGM 2026

Jun 10, 2026, 8:30 AM EDT - 2 months ago

Ocular Therapeutix Transcript: AGM 2026

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Jun 4, 2026, 7:00 AM EDT - 2 months ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Jun 2, 2026, 7:00 AM EDT - 2 months ago

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Ocular Therapeutix Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 2:30 PM EDT - 3 months ago

Ocular Therapeutix Transcript: Stifel 2026 Virtual Ophthalmology Forum

Ocular Therapeutix Slides: FY 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Ocular Therapeutix Slides: FY 2026

Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 6:40 PM EDT - 3 months ago

Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026

Ocular Therapeutix Slides: Association for Research in Vision and Ophthalmology presentation

May 7, 2026, 7:00 AM EDT - 3 months ago

Ocular Therapeutix Slides: Association for Research in Vision and Ophthalmology presentation

Ocular Therapeutix Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Ocular Therapeutix Earnings Call Transcript: Q1 2026

Ocular Therapeutix Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Ocular Therapeutix Earnings release: Q1 2026

Ocular Therapeutix Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Ocular Therapeutix Quarterly report: Q1 2026

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

2026-05-05T11:59:32.000Z - 3 months ago

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

May 5, 2026, 7:00 AM EDT - 3 months ago

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Ocular Therapeutix Proxy statement: Proxy filing

Ocular Therapeutix Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Ocular Therapeutix Proxy statement: Proxy filing

Ocular Therapeutix enrolls first patient in Axpali trial

2026-04-29T13:00:19.000Z - 3 months ago

Ocular Therapeutix enrolls first patient in Axpali trial

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Apr 29, 2026, 7:00 AM EDT - 4 months ago

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Apr 28, 2026, 7:00 AM EDT - 4 months ago

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Ocular Therapeutix Transcript: HCW @ Home

Apr 27, 2026, 2:30 PM EDT - 4 months ago

Ocular Therapeutix Transcript: HCW @ Home

Ocular Therapeutix reports additional Axpaxli trial data

2026-04-13T11:22:45.000Z - 4 months ago

Ocular Therapeutix reports additional Axpaxli trial data

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Apr 13, 2026, 7:00 AM EDT - 4 months ago

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix Slides: 14th Annual Vit-Buckle Society Meeting presentation

Apr 11, 2026, 7:00 AM EDT - 4 months ago

Ocular Therapeutix Slides: 14th Annual Vit-Buckle Society Meeting presentation

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Apr 1, 2026, 7:00 AM EDT - 5 months ago

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Ocular Therapeutix Transcript: RBC Capital Markets Virtual Ophthalmology Conference

Mar 25, 2026, 9:30 AM EDT - 5 months ago

Ocular Therapeutix Transcript: RBC Capital Markets Virtual Ophthalmology Conference

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

Mar 20, 2026, 5:24 PM EDT - 5 months ago

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

EYPT

Ocular Therapeutix Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 9:00 AM EDT - 5 months ago

Ocular Therapeutix Transcript: The Citizens Life Sciences Conference 2026

Ocular Therapeutix price target raised to $27 from $24 at BofA

2026-03-03T11:45:13.000Z - 6 months ago

Ocular Therapeutix price target raised to $27 from $24 at BofA

Ocular Therapeutix price target raised to $28 from $21 at Clear Street

2026-03-02T21:05:53.000Z - 6 months ago

Ocular Therapeutix price target raised to $28 from $21 at Clear Street

Ocular Therapeutix Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 6 months ago

Ocular Therapeutix Transcript: TD Cowen 46th Annual Health Care Conference

Ocular Therapeutix Transcript: Study update

Mar 2, 2026, 7:30 AM EST - 6 months ago

Ocular Therapeutix Transcript: Study update

Ocular Therapeutix Slides: 49th Annual Macula Society Meeting presentation

Feb 27, 2026, 7:00 AM EST - 6 months ago

Ocular Therapeutix Slides: 49th Annual Macula Society Meeting presentation

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 19, 2026, 10:41 AM EST - 6 months ago

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Ocular Therapeutix selloff brings attractive entry point, says Citizens

2026-02-17T19:15:34.000Z - 6 months ago

Ocular Therapeutix selloff brings attractive entry point, says Citizens

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

2026-02-17T15:55:17.000Z - 6 months ago

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

Ocular Therapeutix Transcript: Study result

Feb 17, 2026, 8:00 AM EST - 6 months ago

Ocular Therapeutix Transcript: Study result

Ocular Therapeutix Press release: Study result

Feb 17, 2026, 8:00 AM EST - 6 months ago

Ocular Therapeutix Press release: Study result

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

2026-02-17T12:17:53.000Z - 6 months ago

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

Feb 17, 2026, 7:08 AM EST - 6 months ago

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

REGN

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Feb 13, 2026, 5:00 PM EST - 6 months ago

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 6, 2026, 4:01 PM EST - 6 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

2026-02-05T12:05:13.000Z - 6 months ago

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

Ocular Therapeutix Annual report: Q4 2025

Feb 5, 2026, 7:00 AM EST - 6 months ago

Ocular Therapeutix Annual report: Q4 2025

Ocular Therapeutix Earnings release: Q4 2025

Feb 5, 2026, 7:00 AM EST - 6 months ago

Ocular Therapeutix Earnings release: Q4 2025

Ocular Therapeutix Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:30 AM EST - 9 months ago

Ocular Therapeutix Transcript: Piper Sandler 37th Annual Healthcare Conference

Ocular Therapeutix Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 9:30 AM EST - 9 months ago

Ocular Therapeutix Transcript: Jefferies London Healthcare Conference 2025

Ocular Therapeutix Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Ocular Therapeutix Earnings Call Transcript: Q3 2025

Ocular Therapeutix Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Ocular Therapeutix Quarterly report: Q3 2025

Ocular Therapeutix Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Ocular Therapeutix Earnings release: Q3 2025

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 7:05 AM EST - 10 months ago

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Nov 4, 2025, 7:00 AM EST - 10 months ago

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Oct 7, 2025, 7:00 AM EDT - 11 months ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix Transcript: Investor Day 2025

Sep 30, 2025, 2:00 PM EDT - 11 months ago

Ocular Therapeutix Transcript: Investor Day 2025

Ocular Therapeutix Press release: FY 2025

Sep 30, 2025, 2:00 PM EDT - 11 months ago

Ocular Therapeutix Press release: FY 2025

Ocular Therapeutix Slides: FY 2025

Sep 30, 2025, 2:00 PM EDT - 11 months ago

Ocular Therapeutix Slides: FY 2025

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Sep 30, 2025, 7:08 AM EDT - 11 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Sep 30, 2025, 6:21 AM EDT - 11 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Ocular Therapeutix Slides: FY 2025

Sep 19, 2025, 7:00 AM EDT - 11 months ago

Ocular Therapeutix Slides: FY 2025

Ocular Therapeutix Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 12:50 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Baird Global Healthcare Conference 2025

Ocular Therapeutix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 2:35 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Ocular Therapeutix Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 2:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Ocular Therapeutix Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q2 2025

Ocular Therapeutix Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Quarterly report: Q2 2025

Ocular Therapeutix Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings release: Q2 2025

Ocular Therapeutix Slides: American Society of Retina Specialists presentation

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Slides: American Society of Retina Specialists presentation

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 26, 2025, 1:54 PM EDT - 1 year ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Ocular Therapeutix Slides: FY 2025

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Slides: FY 2025

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Jun 16, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Ocular Therapeutix Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Stifel 2025 Virtual Ophthalmology Forum

Ocular Therapeutix Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 4:30 PM EDT - 1 year ago

Ocular Therapeutix Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Ocular Therapeutix Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 2:35 PM EDT - 1 year ago

Ocular Therapeutix Transcript: RBC Capital Markets Global Healthcare Conference 2025

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

May 14, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Ocular Therapeutix Transcript: Bank of America 2025 Healthcare Conference

May 13, 2025, 12:20 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Bank of America 2025 Healthcare Conference

Ocular Therapeutix Slides: FY 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Slides: FY 2025

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 9:00 AM EDT - 1 year ago

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference 2025

Ocular Therapeutix Quarterly report: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Quarterly report: Q1 2025

Ocular Therapeutix Earnings release: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings release: Q1 2025

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: 24th Annual Needham Virtual Healthcare Conference

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Ocular Therapeutix Slides: Corporate Presentation

Mar 27, 2025, 7:00 PM EDT - 1 year ago

Ocular Therapeutix Slides: Corporate Presentation

Ocular Therapeutix Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 10:00 AM EDT - 1 year ago

Ocular Therapeutix Transcript: Leerink Global Healthcare Conference 2025

Ocular Therapeutix Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:50 AM EST - 1 year ago

Ocular Therapeutix Transcript: TD Cowen 45th Annual Healthcare Conference

Ocular Therapeutix Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q4 2024

Ocular Therapeutix Annual report: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Annual report: Q4 2024

Ocular Therapeutix Earnings release: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings release: Q4 2024

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 24, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Feb 3, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Jan 14, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Ocular Therapeutix Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:15 PM EST - 1 year ago

Ocular Therapeutix Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 1:30 PM EST - 1 year ago

Ocular Therapeutix Transcript: Piper Sandler 36th Annual Healthcare Conference

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Dec 2, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 26, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Ocular Therapeutix Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q3 2024

Ocular Therapeutix Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Quarterly report: Q3 2024

Ocular Therapeutix Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings release: Q3 2024

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 13, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Nov 6, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 15, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Oct 9, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 3:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 25, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Ocular Therapeutix Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 11, 2024, 8:30 AM EDT - 2 years ago

Ocular Therapeutix Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 5, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at September Retina Meetings

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Sep 4, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Ocular Therapeutix Earnings Call Transcript: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Earnings Call Transcript: Q2 2024

Ocular Therapeutix Quarterly report: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Quarterly report: Q2 2024

Ocular Therapeutix Earnings release: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Earnings release: Q2 2024

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 2 years ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 31, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 30, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 13, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Ocular Therapeutix Transcript: Investor Day 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: Investor Day 2024

Ocular Therapeutix Slides: FY 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Slides: FY 2024

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 4, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix Transcript: BofA Securities 2024 Health Care Conference

May 15, 2024, 6:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: BofA Securities 2024 Health Care Conference

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 1:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference

Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

Ocular Therapeutix Quarterly report: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Ocular Therapeutix Quarterly report: Q1 2024

Ocular Therapeutix Earnings release: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Ocular Therapeutix Earnings release: Q1 2024

Ocular Therapeutix Proxy statement: Proxy Filing

May 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2024, 8:16 PM EDT - 2 years ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

May 6, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

May 3, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

May 1, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

SmokenTuna
SmokenTuna Aug. 19 at 12:52 PM
$OCUL going to blow!
0 · Reply
StarLord13
StarLord13 Aug. 19 at 12:49 PM
$OCUL
0 · Reply
Kashking03
Kashking03 Aug. 19 at 12:35 PM
$OCUL @ShortSuckieTuckie ..xbi is almost 3% up in PM..so di we see this run to 12$+
0 · Reply
nicky7
nicky7 Aug. 19 at 12:19 PM
$OCUL give me 25 eoy
0 · Reply
Aaronpell
Aaronpell Aug. 19 at 12:06 PM
$OCUL
0 · Reply
acdurham
acdurham Aug. 19 at 12:04 PM
$OCUL
0 · Reply
Jjarnold44
Jjarnold44 Aug. 19 at 12:03 PM
$OCUL.
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Aug. 19 at 11:37 AM
$OCUL
0 · Reply
lilcapman
lilcapman Aug. 18 at 10:00 PM
$OCUL https://x.com/semodough/status/2089822699052826728
0 · Reply
ES808
ES808 Aug. 18 at 7:46 PM
$OCUL 34 and +.
1 · Reply
ES808
ES808 Aug. 18 at 7:45 PM
$OCUL We’re almost at $11… for those who bought or averaged down around $7–8, it’s already a win. But we’re smart guys. No reason to sell this shit now that it’s been so thoroughly de-risked over the past few months. $20? Hmm, maybe we’d agree to that. But probably not. $30? Now that’s a serious, man-to-man conversation.
1 · Reply
CapitalMonk
CapitalMonk Aug. 18 at 7:24 PM
$OCUL Price: $11.06 (+3.85%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±3.60% RSI: 85.0 | Momentum: Strong Momentum Volume: +25.4% vs avg Volatility: 3.01% Support: $8.15 | Resistance: $11.22 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
Appulen
Appulen Aug. 18 at 7:00 PM
$OCUL My take the price will park itself around the $3B or $15 per share, waiting for the next relevant trigger which could be the NDA filling or a BO offer. My take Dugel will only sell at $30 a share, he has a truckload of incentive shares waiting for him at this share price milestone. If there are competing BO bids maybe it could go 35-44 a share or 8-10B. My investment thesis tells me BO is stronger than ever. Perhaps as soon as the NDA is filed, but before FDA approval.
2 · Reply
stockmoe12
stockmoe12 Aug. 18 at 6:52 PM
$OCUL im thinking $4 B low range and $6B high range
1 · Reply
stockmoe12
stockmoe12 Aug. 18 at 6:51 PM
$OCUL any buyout rumors ?? l think now ocul story is rock solid for buyout around $4-6 range ?
2 · Reply
Lixothetinman
Lixothetinman Aug. 18 at 6:50 PM
$OCUL this bodes well.
0 · Reply
DrKyle
DrKyle Aug. 18 at 6:47 PM
$OCUL curious what the long term investors short term expectations are as far as market cap is with the recent events....do we settle in at 2.5B, 2.75B, 3B, 3.25B +?
2 · Reply
Bbbb44444
Bbbb44444 Aug. 18 at 5:54 PM
$OCUL OMG Teabag is so bad at this. If I keep doing the opposite of whatever he says, I’m gonna be retired by the end of the month.
1 · Reply
NotthenextWarrenBuffet
NotthenextWarrenBuffet Aug. 18 at 5:39 PM
$OCUL admittedly have zero clue what this is but I’m up 7% since my AI trader bought in. And then added more today. To the moon we go I guess
1 · Reply
TBillyhatesmoney
TBillyhatesmoney Aug. 18 at 5:39 PM
$OCUL I’m back!
0 · Reply
MaxKlim
MaxKlim Aug. 18 at 5:32 PM
$OCUL somebody buying …. Go go go
0 · Reply
eastman71
eastman71 Aug. 18 at 5:22 PM
$OCUL Real float here, please? Thanks
1 · Reply